The wholly-owned subsidiary Huadong Medicine has received notification from the FDA in the USA that the clinical trial application for the HDM1005 injection drug submitted by Huadong Medicine has been approved, allowing for Phase I clinical trials to be conducted in the USA. This product is used for the treatment of heart failure with preserved ejection fraction (HFpEF) in obese patients. The HDM1005 injection is a long-acting dual-target agonist for human GLP-1 receptors and GIP receptors. GLP-1 products have effects such as weight loss, blood sugar reduction, and cardiovascular benefits, making them relatively mature and safe targets.
华东医药：子公司HDM1005注射液药品临床试验申请获美国FDA批准
Huadong Medicine: The clinical trial application for the HDM1005 injection drug by the subsidiary has been approved by the FDA in the USA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.